Select Page

In a changing healthcare landscape, delivering value requires true vision.

Adamis is currently developing products in various therapeutic areas including respiratory disease, allergy and opioid overdose. Adamis will pursue 505 (b) (2) regulatory approval filings whenever possible in order to minimize costs and shorten the time to market. The focus is to create high quality, lower-cost therapeutic alternatives to existing treatments.

SYMJEPI® (epinephrine)2 Injection 0.3mg Injectable Anaphylaxis phase-2 phase-3 phase-4
SYMJEPI® (epinephrine)2 Injection 0.15mg Injectable Anaphylaxis phase-2 phase-3 phase-4
ZIMHI(naloxone)2,3 Injection 5mg Injectable Opioid Overdose phase-2 phase-3  
APC-410 (tempol)4 Topical Gel Topical Radiation Dermatitis      

APC-400 (tempol)5

Oral Capsule/Tablet

Oral Respiratory Disease / Anti-Inflammatory      
APC-1000 (beclomethasone)6 Metered Dose Inhaler Inhaler Asthma      
APC-4000 (fluticasone)7 Dry Powder Inhaler Inhaler Asthma      
Phase 1: Clinical trials are typically conducted with a small number of patients or healthy subjects to evaluate safety, determine safe dosage range, identify side effects, and, if possible, gain early evidence of effectiveness.
Phase 2: Clinical trials are conducted with a larger group of patients to evaluate effectiveness of an investigational drug for a defined patient population, and to determine common short-term side effects and risks associated with the drug.
Phase 3: Clinical trials involve large scale, multi-center, comparative trials that are conducted with patients affected with a target disease to evaluate the overall benefit-risk relationship of the investigational drug and to provide an adequate basis for product labeling.

1 Represents the next development/regulatory stage Adamis intends to pursue 2 Licensed U.S. commercial rights to US WorldMeds 3 FDA action date (PDUFA) November 2020 4 Phase II completed, Phase III ready 5 Phase II/III ready 6 FDA approved Phase III study, development suspended to prioritize other products. 7 Development suspended to prioritize other products.